Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer

Clinical Trial Details

This clinical trial is for men (18 years or older) with metastatic castration-resistant prostate cancer (mCRPC).
   
The purpose of this study is to identify a dose of JANX007 that is well tolerated. 
   
JANX007 is experimental, which means that they are being tested and are not yet approved by the United States Food and Drug Administration (FDA).
   
In this study, JANX007 will be given intravenously (meaning through a needle in the vein directly into the blood) weekly. The dose of JANX007 for each participant will depend on their dose regimen cohort assignment.

Participation in this research is expected to last about 18 to 36 weeks.

Key Eligibility: 
  1. Open to men above the age of 18 who have been diagnosed with Metastatic Castration-Resistant Prostate Cancer
  2. Participants must not have had prior solid organ transplant

Detailed eligibility will be reviewed when you contact the study team.
   

Return to List

Study contact by location

Upper East Side - Manhattan

Contact(s)


646-962-2072
guonc@med.cornell.edu

Primary Investigator(s)

Scott T. Tagawa, MD, MS

Protocol ID(s)

Weill Cornell Medicine IRB #:

2402027117

ClinicalTrials.gov:

NCT05519449

Sponsor:

PSMA-007-001

Status

Open to Enrollment

Age Group

Adult

Sponsor

  • Janux Therapeutics, Inc.

Disease

Prostate Cancer